Ethanol enhances the mitogen-driven lymphocyte proliferation in patients with psoriasis

Acta Dermato-Venereologica

Volumn 76, Issue 4, 1996, Pages 260-263

  Schopf, Rudolf E ^a   Ockenfels, Hans M ^a   Morsches, Bernd ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; PHYTOHEMAGGLUTININ;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; PSORIASIS;

ADULT; AGED; AGED, 80 AND OVER; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MIDDLE AGED; MITOGENS; PHYTOHEMAGGLUTININS; PSORIASIS; THYMIDINE; TRITIUM;

EID: 0030056087     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chaput JC, Roynard T, Naveau S, Penso D, Durrmeyer O, Suplisson D. Psoriasis, alcohol, and liver disease. Br Med J Clin Res 1985; 291: 25.
2. Vincenti GE, Blunden SM. Psoriasis and alcohol abuse. J R Army Med Corps 1987; 133: 77-78.
3. Braathen LR, Botten G, Bjerkedal T. Psoratics in Norway. A questionnaire study on health status, contact with paramedical professions, and alcohol and tobacco consumption. Acta Derm Venereol (Stockh) 1989; Suppl 142: 9-12.
4. Evstafév VV, Levin MM. Dermatologic pathology in chronic alcoholics. Vestn Dermatol Venerol 1989: 72-74.
5. Knopf B, Geyer A, Roth H, Barta U. The impact of endogenous and exogenous trigger factors on the course of psoriasis. Dermatol Monatsschr 1989; 175: 242-246.
6. Zanetti G, Peserico A, Grosso G, Biffanti S, Sartori E. Enhanced prevalence of red blood cell macrocytosis in psoriatic patients. A sign of ethanol abuse? Acta Derm Venereol (Stockh) 1989; Suppl 146: 196-198.
7. Poikolainen K, Reunala T, Karvonen J, Lauharanta J, Päivi Kärkkäinen. Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ 1990; 300: 780-783.
8. Naldi L, Parazzini F, Brevi A, Peserico A, Veller-Fornasa C, Grosso G, et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 1992; 127: 212-217.
9. Higgins EM, du Vivier AW. Alcohol and the skin. Alcohol Alcohol 1992; 27: 595-602.
10. Gupta MA, Schork NJ, Gupta AK, Ellis CN. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol 1993; 28: 730-732.
11. Mufti SI. An animal model of immune response associated with alcohol-related cancers. Prog Clin Biol Res 1990; 325: 359-371.
12. Jerrells TR, Smith W, Eckardt MJ. Murine model of ethanol-induced immunosuppression. Alcohol Clin Exp Res 1990; 14: 546-550.
13. Jerrells TR, Perritt D, Eckardt MJ, Marietta C. Alterations in interleukin-2 utilization by T-cells from rats treated with an ethanol-containing diet. Alcohol Clin Exp Res 1990; 14: 245-249.
14. Schopf RE, Trompeter M, Bork K, Morsches B. Effects of ethanol and acetaldehyde on phagocytic functions. Arch Dermatol Res 1985; 277: 131-137.
15. Valdimarsson H, Baker BS, Jönsöttir I, Fry L. Psoriasis, a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986; 7: 256-259.
16. Gottlieb AB. Immunologic mechanisms in psoriasis. J Am Acad Dermatol 1988; 18: 1376-1380.
17. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968; Suppl 97: 77-89.
18. Guilhou JJ, Guillot B. Immunity in psoriasis. Int J Dermatol 1984; 23: 394-395.
19. Krueger GG, Hill HR, Jederberg WW. Inflammatory and immune cell function in psoriasis - a subtle disorder. I. In vivo and in vitro survey. J Invest Dermatol 1978; 71: 189-194.
20. Mobacken H, Lindholm L, Magnusson BL. Serum inhibition of lymphocyte proliferative responses to mitogens in psoriasis. Dermatol Monatsschr 1986; 172: 707-713.
21. Rubins AY, Merson AG. Subpopulations of T lymphocytes in psoriasis patients and their changes during immunotherapy. J Am Acad Dermatol 1987; 17: 972-977.
22. Clot J, Guilhou MJ, Anadary M. Immunological aspects of psoriasis. V. T cell subsets and suppressor cell function regulating immune responses in peripheral blood. J Invest Dermatol 1982; 78: 313-315.
23. Gu SQ, Ros AM, von Stedingk LV, Thyresson N. T lymphocyte subpopulations and pokeweed mitogen-induced immunoglobulin synthesis in vitro by mononuclear cells from psoriasis patients. Int Arch Allergy Appl Immunol 1981; 66: 372-381.
24. Levantine A, Brostoff J. Immunological responses of patients with psoriasis and the effect of treatment with methotrexate. Br J Dermatol 1975; 93: 659-666.
25. Kapp A, Piskorski A, Schöpf E. Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. Br J Dermatol 1988; 119: 707-710.
26. Kemmett D, Symons JA, Colver GB, Duff GW. Serum-soluble interleukin 2 receptor in psoriasis. Acta Derm Venereol (Stockh) 1990; 70: 264-267.
27. Schopf RE, Höcher J, Schütz N, Färber L, Morsches B. Psoriasis treatment with etretinate versus cyclosporin A: clinical course and serum concentrations of soluble interleukin-2 receptors and CD8 antigen. Eur J Dermatol 1992; 2: 224-230.
28. Roselle GA, Mendenhall CL. Alteration of in vitro human lymphocyte function by ethanol, acetaldehyde and acetate. J Clin Lab Immunol 1989; 9: 33-38.
29. Chin JH, Goldstein DB. Drug tolerance in biomembranes: a spin label study of the effects of ethanol. Science 1977; 196: 684-685.
30. Morsches B, Benes B, Holzmann H, Henrich B. Penetration kinetics of dehydroepiandrosterone through the erythrocyte membrane. Arch Dermatol Res 1981; 270: 49-55.
31. Atkinson JP, Sullivan TJ, Kelly JP, Parker CW. Stimulations by alcohols of cyclic AMP metabolism in human leukocytes: possible role of cyclic AMP in the anti-inflammatory effects of ethanol. J Clin Invest 1977; 60: 284-294.
32. Bourne HR, Lichtenstein LM, Melmon KL, Henney CS, Weinstein Y, Shearer GM. Modulation of inflammation and immunity by cyclic AMP. Science 1974; 184: 19-28.
33. Evain-Brion D, Rauynaud F, Plet A, Laurent P, Leduc C, Anderson WB. Deficiency of cyclic AMP dependent protein kinases in human psoriasis. Proc Natl Acad Sci USA 1986; 83: 5272-5276.
34. Schopf RE, Färber L, Benes P, Rehder M, Morsches. cAMP binding to protein kinase A in erythrocyte membranes of psoriatic patients under therapy with etretinate or cyclosporin A. Arch Dermatol Res 1992; 284: 19.
35. Kasteler JS, Petersen MJ, Vance JE, Zone JJ. Circulating activated T lymphocytes in autoeczematization. Arch Dermatol 1992; 128: 795-798.
36. Quesda JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet 1986; i: 1466-1468.
37. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Saf 1992; 7: 417-433.
38. Müller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979; 301: 555.